Bobby brings significant expertise in international corporate development and corporate affairs, after leading the organic expansion of the Clintec organization into over 35 new territories from a strategic, organizational, legal and financial perspective. Bobby is an Executive Director within the Clintec International Group and is a member of the global Board of Directors. He also has a keen interest in corporate governance and providing Board level counsel.

At Clintec, Bobby has directed strategic outsourcing solutions from start to finish for the global pharmaceutical industry across the globe. This even includes the definition, development and governance of strategic relationships with several of the top 10 pharmaceutical companies. He is passionate about jointly forming high-performing global solutions with pharmaceutical companies, specifically with regard to the design and implementation of outsourcing governance structures.

Within the pharmaceutical development arena, Bobby was also an Executive Director of a start-up speciality pharmaceutical company, focused on the development and commercialization of anti-cancer assets. He formed the strategic and financial plans, formed the CxO executive team and led the exclusive licensing negotiation of a novel anti-cancer asset for Phase II development of a blue-chip publicly-listed pharmaceutical company. Within this business, Bobby evaluated the commercial viability of over 15 novel anti-cancer compounds.

Bobby currently also serves as a Life Science advisor to institutional investors, and is engaged on their behalf as a Non-Executive Director of a differentiated Contract Manufacturing Organisation (CMO). He is also a member of the GlobalScot organisation, a business development support body formed to advance the prospects and interests of Scottish businesses in international territories.

You might also be interested in…